

To Study the Bacteriological Profile and Antimicrobial Susceptibility Patterns of Pathogens Isolated from Urine Samples in Icu Patients at a Tertiary Care Hospital in North India

Anshika Srivastava^{1*}, Geetanshu Chauhan², Nashra Afaq³

¹PG Student, Department of Microbiology, School of Medical Science and Research, Greater Noida, Uttar Pradesh, India.

²Junior Laboratory Technician, Department of Microbiology, School of Medical Science and Research, Greater Noida, Uttar Pradesh, India

³Assistant Professor, Department of Microbiology and Central Research Laboratory, Rama Medical College Hospital and Research Centre, Uttar Pradesh, India

*Corresponding Author:

Anshika Srivastava,

Email ID: anshikasrivastava8845@gmail.com

Cite this paper as: Anshika Srivastava, Geetanshu Chauhan, Nashra Afaq, (2025) To Study the Bacteriological Profile and Antimicrobial Susceptibility Patterns of Pathogens Isolated from Urine Samples in Icu Patients at a Tertiary Care Hospital in North India. *Journal of Neonatal Surgery*, 14 (32s), 6556-6569.

ABSTRACT

Background: Intensive care units (ICUs) are hotspots for multidrug-resistant (MDR) bacterial infections, which significantly contribute to patient morbidity and mortality. Prompt identification of pathogens and knowledge of their resistance profiles is essential for empirical therapy and infection control.

Aim and Objective: To evaluate the distribution of pathogens from various clinical specimens in ICU patients and to analyze their antibiotic susceptibility patterns.

Material and Methods: A retrospective study was conducted in the Department of Microbiology, Sharda Hospital, Greater Noida, over a defined period. A total of 2,125 clinical samples from ICU patients were processed according to standard microbiological protocols. Identification of isolates was done by biochemical testing, and antimicrobial susceptibility was determined by the Kirby-Bauer disk diffusion method as per CLSI guidelines (2023) [1].

Results: In the present study out of the 2,125 samples, blood constituted 46%, urine 30%, respiratory 20%, and pus 4%. A total of 285 pathogens were isolated, with respiratory samples showing the highest positivity (46%). The most common organisms were *E. coli* (24%), *Acinetobacter* spp. (23%), *Klebsiella* spp. (13%), and *Staphylococcus aureus* (10%). Among Enterobacteriaceae, carbapenems (43%), tigecycline (43%), and aminoglycosides (41–42%) were the most effective drugs. *Acinetobacter* spp. showed high sensitivity to minocycline (68%) and tigecycline (45%) but complete resistance to nitrofurantoin and norfloxacin. *Pseudomonas aeruginosa* responded well to amikacin (79%) and carbapenems (75%). Gram-positive isolates like *S. aureus* and *Enterococcus* spp. were highly susceptible to linezolid (95–100%) and vancomycin (50–78%).

Conclusion: The findings highlight a high burden of multidrug-resistant pathogens in ICU settings, with varying resistance patterns requiring continuous surveillance and rational antimicrobial stewardship.

Keywords: Bacteriological, Profile, Antimicrobial Susceptibility Patterns, Icu, Blood, Clsi

1. INTRODUCTION

Intensive Care Units (ICUs) are considered critical care environments where patients are at heightened risk of acquiring healthcare-associated infections (HAIs), primarily due to invasive procedures, prolonged hospital stays, and immunocompromised conditions. These settings often harbor multidrug-resistant (MDR) organisms, making infection control and effective antimicrobial therapy essential components of ICU management [1]. The growing threat of antimicrobial resistance (AMR) in ICUs is a global public health concern, as it leads to increased morbidity, mortality, and economic burden [2,3].

The bacteriological profile in ICUs is typically dominated by Gram-negative organisms such as *Acinetobacter* spp., *Klebsiella* spp., *Pseudomonas aeruginosa*, and *Escherichia coli*, along with Gram-positive pathogens like *Staphylococcus aureus* and *Enterococcus* spp. [4-6]. These organisms are notorious for exhibiting resistance to multiple classes of antibiotics, including carbapenems, cephalosporins, aminoglycosides, and fluoroquinolones [7]. Moreover, the increasing incidence of extended-spectrum β -lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE) has further complicated the management of ICU infections [8].

Recent studies in India and globally have shown that antibiotic resistance patterns vary with geography, hospital policies, and antibiotic stewardship practices [9]. The World Health Organization (WHO) has identified priority pathogens that require urgent research and development of new antimicrobials, with many ICU pathogens making the list. Surveillance studies help in formulating local antibiograms, guiding empirical therapy, and minimizing therapeutic failures [10].

In India, studies have reported a rising trend in resistance to first-line antibiotics, with some centers noting up to 70–80% resistance in ICU isolates, particularly among *Acinetobacter* and *Klebsiella* species [11]. The Clinical and Laboratory Standards Institute (CLSI) guidelines provide standardized methods for antimicrobial susceptibility testing, enabling laboratories to detect resistance trends and contribute to national and global surveillance efforts.

Understanding the local bacteriological profile and antibiotic susceptibility patterns is critical for implementing targeted therapy and infection control strategies. This is especially relevant in tertiary care hospitals where ICUs manage a diverse range of critically ill patients, including those with ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and surgical site infections [12].

Therefore, this study was undertaken to identify the distribution of bacterial pathogens isolated from ICU patients and analyze their antimicrobial susceptibility patterns. The results will help in guiding clinicians for appropriate empiric therapy and contribute to improved antimicrobial stewardship and infection prevention policies in the ICU setting.

2. MATERIAL AND METHODS

This retrospective study was conducted in the Bacteriology Division of the Department of Microbiology at Sharda Hospital, Greater Noida, a tertiary care center in North India. During the study period, 2,125 clinical samples were collected from ICU patients, including blood (988), urine (627), respiratory samples (420), and pus (90).

All specimens were processed using standard microbiological techniques. Culture was performed on appropriate media, and bacterial isolates were identified based on colony morphology, Gram staining, and standard biochemical tests.

Type of Sample - Blood, Central line tips, Broncho-alveolar lavage (BAL), Pleural fluid, Cerebrospinal Fluid (CSF), Ascitic fluid, Endotracheal aspirate, Pus or Tissue, sputum, throat swab, Urine samples received for culture and sensitivity.

Antimicrobial susceptibility testing (AST) was performed using the Kirby-Bauer disk diffusion method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines (2023) [13]. The antibiotics tested included beta-lactams, aminoglycosides, fluoroquinolones, carbapenems, and others relevant to Gram-negative and Gram-positive pathogens. Data were recorded and analyzed to assess the prevalence of organisms and their resistance profiles.

Inclusion Criteria- Blood, Central line tips, Broncho-alveolar lavage (BAL), Pleural fluid, Cerebrospinal Fluid (CSF), Ascitic fluid, Endotracheal aspirate, Pus or Tissue, sputum, throat swab, Urine received in Microbiology Section, Bacteriology Laboratory.

Exclusion Criteria-

1. Sputum showing 10 or more squamous epithelial cells per low power field on gram stain.
2. Bacterial isolates identified as commensals or contaminants.
3. Mixed bacterial growth.
4. Excessive delay between specimen collection and arrival in laboratory.

The experimental group includes the patients undergo treatment by Driftodontics based upon the philosophy of Alexander Discipline and control group includes the patient undergo by conventional MBT treatment.

3. RESULTS

During the study period, a total of 2,125 samples were received from various ICUs and analyzed in the Bacteriology Lab at Sharda Hospital, Greater Noida. Out of the 2,125 ICU samples analyzed, blood was the most common specimen (46%), followed by urine (30%), respiratory samples (20%), and pus (4%). From these, 285 bacterial isolates were obtained, with respiratory samples yielding the highest number (131, 46%), followed by blood (64, 23%), urine (58, 20%), and pus (32, 11%). The most common organisms across all samples were *Escherichia coli* (69, 24%), *Acinetobacter* spp. (65, 23%), *Klebsiella* spp. (38, 13%), *Pseudomonas aeruginosa* (28, 10%), *Staphylococcus aureus* (28, 10%), *Enterococcus* spp. (28,

10%), coagulase-negative Staphylococci (17, 6%), and Citrobacter spp. (10, 3%). Among Enterobacteriaceae, carbapenems (meropenem and imipenem) and tigecycline were the most effective agents (43%), followed by gentamicin (42%) and amikacin (41%). Nitrofurantoin showed high efficacy (70%) in urinary tract infections, while norfloxacin was the least effective (10%). Acinetobacter spp. displayed alarming resistance, with only minocycline (68%) and tigecycline (45%) showing moderate activity. Carbapenems, cephalosporins, and fluoroquinolones had <5% sensitivity. Pseudomonas aeruginosa showed good susceptibility to amikacin (79%), gentamicin, and carbapenems (75%).

The distribution of these samples were as follows- 988 blood samples (46%), 627 urine samples (30%), 420 respiratory samples (20%), and 90 pus samples (4%).(Table1).

Sample Type	No.of samples (Percentage)
Blood	988 (46%)
Urine	627 (30%)
Respiratory samples	420 (20%)
Pus	90 (4%)

Table 1: Total Samples Collected from ICUs (n=2125)




Fig1-Total Samples Collected from ICUs

A total of 285 clinical isolates have been obtained from various samples collected across different ICUs. Respiratory samples showed the highest isolation rate, with 131 isolates (46%), followed by blood samples with 64 isolates (23%), urine samples with 58 isolates (20%), and pus samples with 32 isolates (11%). (Table 2)

Sample Type	No.of isolates (Percentage)
Blood	64 (23%)
Urine	58 (20%)
Respiratory samples	131 (46%)
Pus	32 (11%)

Table 2: Sample wise distribution of isolates (n=285)




Fig2-Sample wise distribution of isolates

The most frequently isolated organisms were *Staphylococcus aureus* (including both *MRSA* and *MSSA*) and *Coagulase-negative staphylococci (CONS)* with 17 isolates (27%), followed by *Klebsiella spp.* with 10 isolates (16%), *E. coli* with 8 isolates (12%), *Acinetobacter spp.* With 6 isolates (9%), and *Enterococcus spp.* with 4 isolates (6%). *Pseudomonas spp.* was the least isolated organism, with only 2 isolates (3%) in bloodstream infections. (Table 3.1)

Urine samples (n=58)

Causative Organisms	Numbers(Percentage)
<i>E.coli</i>	23 (40%)
<i>Enterococcus spp.</i>	23 (40%)
<i>Klebsiella spp.</i>	6 (9%)
<i>Pseudomonas spp.</i>	3 (5%)
<i>Acinetobacter spp.</i>	1 (2%)
<i>Citrobacter spp.</i>	1 (2%)
<i>Staphylococcus spp. (MSSA)</i>	1 (2%)

Table 3: Etiological distribution of Urinary tract infections





Fig 3 Etiological distribution of Urinary tract infections

In respiratory tract infections, *Acinetobacter* spp. was the most frequently isolated organism, with 54 isolates (41%) followed by *E. coli* with 27 isolates (21%), *Pseudomonas* spp. with 21 isolates (16%), *Klebsiella* spp. with 17 isolates (13%), and *Staphylococcus aureus* (both MRSA and MSSA) with 8 isolates (6%). *Citrobacter* spp. was the least isolated organism, with only 4 isolates (3%). (Table 3.3)

In Total samples (n=285)

Causative organisms	Numbers(Percentage)
<i>E. coli</i>	69 (24%)
<i>Acinetobacter</i> spp.	65 (23%)
<i>Klebsiella</i> spp.	38 (13%)
<i>Pseudomonas</i> spp.	28 (10%)
<i>Staphylococcus aureus</i> (MRSA and MSSA)	28 (10%)
<i>Enterococcus</i> spp.	28 (10%)
CONS	17 (6%)
<i>Citrobacter</i> spp.	10 (3%)
<i>Proteus</i> spp.	2 (1%)

Table 4: Overall distribution of microorganisms causing infections in ICUs



Ward wise distribution	No. of cases
EICU-	2
ICCU-	13
MICU-	14
NeuroICU-	1
PICU-	4
RICU-	9
SICU-	13
NICU-	2

Table 5: Wardwise distribution of cases

The antimicrobial susceptibility profiles of all Gram-negative and Gram-positive bacteria (GNB and GPC) isolates (n = 285) were determined using the Clinical and Laboratory Standards Institute (CLSI) disk diffusion method.

Enterobacteriaceae

- Carbapenems (meropenem, imipenem) and tigecycline were the most effective antibiotics, showing a 43% efficacy, followed by gentamicin (42%), amikacin (41%), minocycline (39%), cotrimoxazole (35%), and tobramycin (31%). Ampicillin was the least effective, with an efficacy of only 8%.
- In urinary tract infections, nitrofurantoin showed the highest efficacy (70%), while norfloxacin was the least effective (10%).
- Fosfomycin demonstrated high effectiveness, with 66% efficacy in both urinary and respiratory tract infections.

Antibiotics	Sensitivity (%)	Resistance (%)
Ampicillin	8%	92%
Gentamicin	42%	58%
Tobramycin	31%	69%
Amoxyclav	22%	78%
Ceftriaxone	26%	74%
Cefotaxime	26%	74%
Cefuroxime	12%	88%
Cefepime	22%	78%
Ciprofloxacin	26%	74%
Levofloxacin	26%	74%
Amikacin	41%	59%
Imipenem	43%	57%
Meropenem	43%	57%
Piperacillin/tazobactam	27%	73%
Cotrimoxazole	35%	65%
Ceftazidime	13%	87%
Aztreonam	19%	81%
Tetracycline	26%	74%
Minocycline	39%	61%
Tigecycline	43%	57%
Nitrofurantoin	70%	30%
Fosfomycin	66%	34%
Norfloxacin	10%	90%

Table 6: Antibiotic susceptibility profile of *Enterobacteriaceae*(n=119)




Fig 5-Antibiotic sensitive profile of *Enterobacteriaceae*(n=119)

Non-Enterobacteriaceae-Among the 285 isolates, 65 were as *Acinetobacter*spp, and 28 as *Pseudomonas*spp.


1-*Acinetobacter* spp.

A total of 65 *Acinetobacter* species were isolated from 285 isolates. *Acinetobacter* spp. were found to be highly effective for Minocycline (68%) followed by Tigecycline (45%), Cotrimoxazole (15%), Ceftriaxone and Cefotaxime (14%) whereas, Meropenem, Imipenem, Cefepime and Cefuroxime were least effective (1%) among all the antibiotic agents tested.

Nitrofurantoin and Norfloxacin showed resistant to all the isolates of *Acinetobacter* spp. in urinary tract infection.

Antibiotics	Sensitivity(%)	Resistance(%)
Ceftazidime	4%	96%
Ciprofloxacin	4%	96%
Levofloxacin	4%	96%
Gentamicin	4%	96%
Tobramycin	5%	95%
Imipenem	1%	99%
Meropenem	1%	99%
Ceftriaxone	14%	86%
Cefotaxime	14%	86%
Cefepime	1%	99%
Amikacin	7%	93%
Piperacillin/tazobactam	7%	93%
Minocycline	68%	32%

Cotrimoxazole	15%	85%
Tigecycline	45%	55%
Cefuroxime	1%	99%
Tetracycline	6%	94%
Nitrofurantoin	0%	100%
Norfloxacin	0%	100%

Table 7: Antibiotic susceptibility pattern of *Acinetobacterspp.*(n=65)Fig6-Antibiotic sensitive pattern of *Acinetobacterspp.*(n=65)

2-*Pseudomonas aeruginosa* Aminoglycosides (Amikacin, Gentamicin, Tobramycin) were found to be highly effective(79%,75%,75%) followed by Carbapenems (meropenem, imipenem) (75%) Cefepime (75%) and flouroquinolones (Ciprofloxacin, Levofloxacin) (60%) respectively. whereas, Piperacillin-tazobactum was least effective (53%).

Nitrofurantoin and Norfloxacin showed resistant to all the isolates of *Pseudomonas aeruginosa* in urinary tract infection.

Antibiotics	Sensitivity(%)	Resistance(%)
Ceftazidime	58%	42%
Gentamicin	75%	25%
Tobramycin	75%	25%
Piperacillin-tazobactum	53%	47%
Cefepime	75%	25%
Ciprofloxacin	60%	40%

Levofloxacin	60%	40%
Amikacin	79%	21%
Imipenem	75%	25%
Meropenem	75%	25%
Aztreonem	67%	33%
Nitrofurantoin	0%	100%
Norfloxacin	0%	100%

Table 8: Antibiotic susceptibility pattern of *Pseudomonas aeruginosa*(n=28)




Fig7-Antibiotic sensitive pattern of *Pseudomonas aeruginosa* (n=28)

Among the 285 isolates, 28 were as *Staphylococcus aureus*, 28 as *Enterococcus* spp. and 17 as *Coagulase negative Staphylococci* (CoNS).

1- *Staphylococcus aureus* and CoNS

Linezolid was found to be highly effective (95%) followed by Vancomycin (86%), Tetracycline (81%), Cotrimaxazole (68%), Gentamicin (63%) and Teicoplanin (46%) whereas, Penicillin was least effective (15%) respectively.

Nitrofurantoin and Norfloxacin was found to be highly effective (100%) in urinary tract infections.

Fosfomycin was found to be highly effective (66%) in urinary tract infections and respiratory tract infections.

Antibiotics	Sensitivity(%)	Resistance(%)
Penicillin	15%	85%
Cefoxitin	37%	63%
Vancomycin	50%	50%
Teicoplanin	46%	54%

Linezolid	95%	5%
Gentamicin	63%	37%
Azithromycin	34%	66%
Erythromycin	28%	72%
Tetracycline	81%	19%
Ciprofloxacin	32%	68%
Levofloxacin	32%	68%
Nitrofurantoin	100%	0%
Clindamycin	28%	72%
Cotrimaxazole	68%	32%
Norflo	100%	0%
Fosfomycin	66%	34%

Table 9: Antibiotic susceptibility pattern of *Staphylococcus aureus* and CoNS (n=45)




Fig8-Antibiotic sensitive pattern of *Staphylococcus aureus* and CoNS (n=45) 2-Enterococcus spp.

Linezolid was found to be highly effective (100%) followed by Teicoplanin (90%), Vancomycin (78%), Ampicillin (33%), High level gentamycin (15%) and High level streptomycin (15%) respectively. Erythromycin showed resistant to all the isolates of *Enterococcus spp.*

Nitrofurantoin was found to be highly effective (60%) whereas Fosfomycin was least effective (18%) respectively and Norfloxacin showed resistant to all the isolates of *Enterococcus spp.* in urinary tract infections.

Antibiotics	Sensitivity(%)	Resistance(%)
Ampicillin	33%	67%
Penicillin	15%	85%
Linezolid	100%	0%
Vancomycin	52%	48%
Highlevel gentamycin	15%	85%
Highlevel streptomycin	15%	85%
Ciprofloxacin	8%	92%
Levofloxacin	8%	92%
Fosfomycin	18%	82%
Nitrofurantoin	60%	40%
Tetracycline	9%	91%
Teicoplanin	90%	10%
Erythromycin	0%	100%
Norflox	0%	100%

Table 10: Antibiotic susceptibility pattern of *Enterococcus* spp.(n=28)




Fig9-Antibiotic sensitive pattern of *Enterococcus* spp.(n=28)

Among Gram-positive bacteria, *S. aureus* and coagulase-negative Staphylococci were most sensitive to linezolid (95%), vancomycin (86%), and tetracycline (81%). *Enterococcus* spp. demonstrated 100% susceptibility to linezolid and 90% to teicoplanin, but showed high resistance to erythromycin, ciprofloxacin, and aminoglycosides.

4. DISCUSSION

This study provides valuable insight into the bacteriological spectrum and antimicrobial susceptibility patterns among ICU patients in a tertiary care hospital. Among 2,125 samples, 285 isolates were identified, predominantly from respiratory specimens, reflecting the burden of ventilator-associated infections.

The predominance of Gram-negative organisms such as *E. coli* (24%), *Acinetobacter* spp. (23%), and *Klebsiella* spp. (13%) mirrors findings from other Indian ICUs [14,15]. *Acinetobacter* spp., in particular, has emerged as a formidable pathogen due to its capacity for biofilm formation and multidrug resistance [16]. In this study, its sensitivity was limited to minocycline (68%) and tigecycline (45%), consistent with reports by Gupta et al. (2021) and Joseph et al. (2020) [18,19].

E. coli and *Klebsiella* spp., the common Enterobacteriaceae, showed moderate sensitivity to carbapenems (43%) and aminoglycosides (41–42%), which is lower than earlier reports indicating 60–70% susceptibility [20,21]. A study in Tamil Nadu found similar resistance patterns, highlighting the rising incidence of ESBL and carbapenem-resistant strains [22]. Fosfomycin and nitrofurantoin maintained good activity in urinary isolates, confirming findings by Singh et al. (2022) [23].

Pseudomonas aeruginosa showed good susceptibility to amikacin and carbapenems (~75%), in agreement with studies from Kerala and Delhi [24,25]. However, resistance to fluoroquinolones and β -lactams continues to rise due to efflux pumps and β -lactamase production [26].

Among Gram-positive cocci, *Staphylococcus aureus* (including MRSA) showed high susceptibility to linezolid (95%) and vancomycin (86%), corroborating studies by Dey et al. (2023) and Ahmed et al. (2021) [27,28]. The high sensitivity to linezolid is promising, but vancomycin-intermediate strains necessitate ongoing surveillance [29]. Similarly, *Enterococcus* spp. displayed 100% sensitivity to linezolid and 90% to teicoplanin, but near-total resistance to erythromycin, reflecting trends observed in multicenter surveillance studies [30,31].

The overall high burden of MDR pathogens in this ICU study aligns with national trends indicating increasing resistance to first-line agents in critical care settings [32]. Antimicrobial stewardship programs, infection control measures, and periodic antibiograms are essential to curtail further resistance [33].

5. CONCLUSION

The study underscores a concerning prevalence of multidrug-resistant organisms in ICU settings, especially *Acinetobacter* spp., *E. coli*, and *Klebsiella* spp. The observed resistance to key antibiotics like carbapenems and aminoglycosides necessitates urgent attention.

Empirical treatment should be tailored based on local antibiogram data, and the use of last-resort antibiotics must be guided strictly by susceptibility testing.

6. LIMITATIONS

1. This was a single-center retrospective study, which may not be generalizable to other settings.
2. Molecular methods for resistance gene detection were not used.
3. Clinical outcomes of patients and infection-related mortality were not analyzed.
4. Viral, fungal, and anaerobic pathogens were not included.

7. DECLARATIONS

Conflicts of interest: There is no any conflict of interest associated with this study

Consent to participate: There is consent to participate.

Consent for publication: There is consent for the publication of this paper.

Authors' contributions: Author equally contributed the work

REFERENCES

- [1] Vincent JL, Rello J, Marshall J, et al. *Int J Antimicrob Agents*. 2009;34(5):365–378.
- [2] Kumar A, Ellis P, Arabi Y, et al. *Crit Care Med*. 2009;37(5):1536–1543.
- [3] Ventola CL. *Pharm Ther*. 2015;40(4):277–283.
- [4] Gandra S, Mojica N, Klein EY, et al. *Clin Infect Dis*. 2019;69(Suppl 5):S340–S345.
- [5] Banerjee T, Anupurba S. *J Infect Public Health*. 2021;14(5):669–675.
- [6] Behera B, Mathur P, Das A, et al. *J Glob Infect Dis*. 2020;12(4):172–179.
- [7] Mehta A, Rosenthal VD, Mehta Y, et al. *Am J Infect Control*. 2007;35(3):144–149.

- [8] Nordmann P, Naas T, Poirel L. *Lancet Infect Dis*. 2011;11(4):228–236.
 - [9] Dey S, Sinha A, Mistry M, et al. *J Clin Diagn Res*. 2022;16(3):DC01–DC05.
 - [10] World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017.
 - [11] Mahajan G, Mishra SK, Kumar M, et al. *Trop Doct*. 2023;53(1):56–60.
 - [12] Kaur R, Gautam V, Ray P. *Indian J Med Microbiol*. 2015;33(2):255–257.
 - [13] Clinical Laboratory Standards Institute, M100-s24: Performance Standards for Antimicrobial Susceptibility testing: Twenty-First Informational Supplement, Clinical Laboratory Standards Institute, Wayne, Pa, USA, 2023 Sharma S, Singh P. *J Clin Diagn Res*. 2020;14(5):DC01–DC05.
 - [14] Patel P, Shah R. *Indian J Crit Care Med*. 2021;25(4):415–421.
 - [15] Vijayakumar S, Kanthan K. *J Infect Dev Ctries*. 2022;16(1):56–62.
 - [16] Kollef MH. *Crit Care Med*. 2005;33(6):1411–1420.
 - [17] Kumar,S.,Adithan,C.,Harish,B.N.,Sujatha,S.,&Roy,G.(n.d.).A.Malini Antimicrobial resistance in India: A review.
 - [18] Gupta E, Mohapatra S. *J Lab Physicians*. 2021;13(2):135–140.
 - [19] Joseph NM, Sistla S. *Indian J Med Microbiol*. 2020;38(1):112–116.
 - [20] Ray P, Garg R. *Indian J Med Res*. 2021;153(6):702–709.
 - [21] Sarma JB, Ahmed GU. *Indian J Crit Care Med*. 2022;26(2):109–113.
 - [22] Arunagiri K, Baskar V. *Int J Med Microbiol Trop Dis*. 2022;8(1):45–49.
 - [23] Singh A, Mandal J. *J Infect Dev Ctries*. 2022;16(10):1656–1662.
 - [24] Thomas R, Nair S. *J Glob Antimicrob Resist*. 2023;32:215–222.
 - [25] Mehta Y, Gupta A. *Indian J Crit Care Med*. 2019;23(11):541–546.
 - [26] Taneja N, Kaur H. *Indian J Med Res*. 2018;147(6):562–570.
 - [27] Dey R, Sengupta P. *J Clin Diagn Res*. 2023;17(2):DC10–DC14.
 - [28] Ahmed Z, Purohit A. *J Infect Dev Ctries*. 2021;15(11):1624–1630.
 - [29] Lebreton F, Willems RJL. *Clin Microbiol Rev*. 2017;30(1):174–201.
 - [30] Prakash R, Arora V. *Indian J Med Microbiol*. 2020;38(4):502–507.
 - [31] Banerjee R, Johnson JR. *Clin Infect Dis*. 2014;58(10):1449–1457.
 - [32] Gandra S, Joshi J. *Lancet Infect Dis*. 2020;20(3):271–273.
 - [33] Laxminarayan R, Matsoso P. *Lancet*. 2016;387(10014):168–175
-